DOSSIER · 13F-HR · Q1 2026

ARCH Venture Management, LLC

$677M in tracked AUM across 10 positions as of Q1 2026.

AV
CIK 0001274403 · last filed Mar 31, 2026
Total AUM
$677M
as of Q1 2026
Holdings
10
positions
Whale Score
73
73
strong
Activity
no data
changes this Q
AI Analysis · Q1 2026

Portfolio Overview

ARCH Venture Management’s 13F filing for the period ending September 30, 2025, reveals a highly concentrated, high-conviction portfolio with a distinct focus on early-stage and clinical-stage biotechnology. The firm manages approximately $384.90 million in assets across just 7 holdings, resulting in an average position size of roughly $55 million. This extreme lack of diversification—nearly 30% of the fund is allocated to a single security—indicates an investment ...

The portfolio experienced significant growth during the quarter, with total assets under management (AUM) increasing by 28.7%, rising from $299.11 million to $384.90 million. This appreciation is likely driven by a combination of market performance in underlying holdings and active capital reallocation. The firm’s activity this quarter was decisive, characterized by a "survival-of-the-fittest" approach where capital was consolidated into existing winners while underperforming or thesis-complete positions were liquidated.

Key Holdings

Analysis generated by 13F Insight from SEC Form 13F filing data · Q1 2026. Methodology

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
MAZE
MAZE THERAPEUTICS INC
$123M4.1M18.2%
02
RAPP
RAPPORT THERAPEUTICS INC
$117M3.7M17.2%
03
VIR
VIR BIOTECHNOLOGY INC
$116M12.9M17.1%
04
ERAS
ERASCA INC
$115M7.1M16.9%
05
BEAM
BEAM THERAPEUTICS INC
$108M4.5M16.0%
06
LYEL
LYELL IMMUNOPHARMA INC
$65M3.2M9.6%
07
GENB
GENERATE BIOMEDICINES INC
$24M1.9M3.6%
08
TXG
10X GENOMICS INC
$5M218K0.7%
09
GOSS
GOSSAMER BIO INC
$3M8.1M0.4%
10
QTTB
Q32 BIO INC
$2M320K0.3%

Filing history

2026Q1Mar 31
$677M 3.9%
10 positionsView →
2025Q4Dec 31
$652M 69.3%
9 positionsView →
2025Q3Sep 30
$385M 28.7%
7 positionsView →
2025Q2Jun 30
$299M 86.6%
11 positionsLocked
2025Q1Mar 31
$160M 30.4%
7 positionsLocked
2024Q4Dec 31
$230M 11.6%
9 positionsLocked
2024Q3Sep 30
$261M 2.1%
9 positionsLocked
2024Q2Jun 30
$266M 231.4%
9 positionsLocked
2024Q1Mar 31
$80M 50.9%
8 positionsLocked
2023Q4Dec 31
$164M 6.2%
7 positionsLocked
2023Q3Sep 30
$154M 4.9%
7 positionsLocked
2023Q2Jun 30
$162M 21.8%
6 positionsLocked
Showing 12 of 26